Patents by Inventor Matthew E. Voss

Matthew E. Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disubstituted polycyclic systems and preparative methods therefor
    Patent number: 5424430
    Abstract: Polycyclic cognition enhancers having the general formula (1a), (1b) or (1c) are provided: ##STR1## wherein: R.sub.1 is a heterocyclic aromatic moiety such as a 4-pyridyl, 2-pyridyl, 4-pyrimidyl, or pyrazinyl group;R.sub.2 and R.sub.3 are independently H, F, Cl, Br, NO.sub.2, CONH.sub.2, CON(R.sub.4)(R.sub.4 '), S(O).sub.m R.sub.4, CF.sub.3, or N(R.sub.4)(R.sub.4 ');R.sub.4 and R.sub.4 ' are independently H, alkyl having from 1 to 4 carbon atoms, CH.sub.2 Phe--W, or Phe--W;Phe is a phenyl group;R.sub.5 is --(CH.sub.2).sub.n --Y or --OCOR.sub.4 ;Y is H, OH, NH.sub.2, NHR.sub.4, N(R.sub.4)(R.sub.4 '), NHCOR.sub.4, NHCO.sub.2 R.sub.4, NHS(O).sub.2 R.sub.4, F, Cl, Br, OR.sub.4, S(O).sub.m R.sub.4, CO.sub.2 H, CO.sub.2 R.sub.4, CN, CON(R.sub.4)(R.sub.4 '), CONHR.sub.4, CONH.sub.2, COR.sub.4, Phe, Phe--W, --C.tbd.CCO.sub.2 R.sub.4, --CH.dbd.CHR.sub.4, --C.tbd.CR.sub.4, or a heterocyclic aromatic moiety such as a 4-pyridyl, 2-pyridyl, 4-pyrimidyl, or pyrazinyl group;W is F, Cl, Br, R.sub.4, OR.sub.4, NO.sub.2, NH.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: June 13, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: James H. Jensen, Timothy D. Costello, Leon De Brabander, Jr., Matthew E. Voss
  • Neurotransmitter releasers useful for cognition enhancement
    Patent number: 5414004
    Abstract: Compounds of the following formula have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man involving learning and cognition, where subnormal levels of this neurochemical are found ##STR1## wherein R.sup.1 is 4-,3-, or 2-pyridyl, 2-fluoro-4-pyridyl or 3-fluoro-4-pyridyl;R.sup.2 is alkyl of 1 to 10 carbons, cycloalkyl of 3 to 8 carbons, 2-,3-, or 4-pyridyl, Phe or Phe-W;Phe is a phenyl group;W is F, Cl, Br, R.sup.4, --OH, --OR.sup.4, --NO.sub.2, --NH.sub.2, --NHR.sup.4, --NR4R.sup.4, --CN, --S(O)m --R.sup.4 ;R.sup.3 is H, F, Cl, Br, --CN, --OH, --NO.sub.2, --NH.sub.2, --CF.sub.3, --NHR.sup.4, --NR.sup.4 R.sup.4, R.sup.4, --OR.sup.4, --S(O).sub.m --R.sup.4R.sup.4 is alkyl of 1 to 4 carbons, CH.sub.2 Phe-- or Phe--;R.sup.5 is --(CH.sub.2).sub.n --Y or --OCOR.sup.4 ;Y is NH.sub.2, --NHR.sup.4, --NR.sup.4 R.sup.4, --NHCOR.sup.4, --NHCO.sub.2 R.sup.4, F, Cl, Br, OR.sup.4, --S(O).sub.m R.sup.4, --CO.sub.2 H, --CO.sub.2 R.sup.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: May 9, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Wendell W. Wilkerson, Richard A. Earl, Matthew E. Voss
  • Bispyridyl-containing heterocycles useful for treating cognitive disorders
    Patent number: 5308851
    Abstract: Bispyridyl-containing heterocycles, or pharmaceutically acceptable salts thereof, are useful in treating neurological disorders in mammals. The compounds have efficacy over a broad dosage ranges as measured in both neurotransmitter release assay and by hypoxia induced cognition deficit.
    Type: Grant
    Filed: June 3, 1993
    Date of Patent: May 3, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Christopher A. Teleha, Matthew E. Voss
  • Disubstituted polycyclic systems and preparative methods therefor
    Patent number: 5272269
    Abstract: Polycyclic cognition enhancers having the general formula (1a), (1b) or (1c) are provided: ##STR1## wherein: R.sub.1 is a heterocyclic aromatic moiety such as a 4-pyridyl, 2-pyridyl, 4-pyrimidyl, or pyrazinyl group;R.sub.2 and R.sub.3 are independently H, F, Cl, Br, NO.sub.2, CONH.sub.2, CON(R.sub.4)(R.sub.4 '), S(O).sub.m R.sub.4, CF.sub.3, or N(R.sub.4)(R.sub.4 ');R.sub.4 and R.sub.4 ' are independently H, alkyl having from 1 to 4 carbon atoms, CH.sub.2 Phe--W, or Phe--W;Phe is a phenyl group;R.sub.5 is --(CH.sub.2).sub.n --Y or --OCOR.sub.4 ;Y is H, OH, NH.sub.2, NHR.sub.4, N(R.sub.4)(R.sub.4 '), NHCOR.sub.4, NHCO.sub.2 R.sub.4, NHS(O).sub.2 R.sub.4, F, Cl, Br, OR.sub.4, S(O).sub.m R.sub.4, CO.sub.2 H, CO.sub.2 R.sub.4, CN, CON(R.sub.4)(R.sub.4 '), CONHR.sub.4, CONH.sub.2, COR.sub.4, Phe, Phe--W, --C.tbd.CCO.sub.2 R.sub.4, --CH.dbd.CHR.sub.4, --C.tbd.CR.sub.4, or a heterocyclic aromatic moiety such as a 4-pyridyl, 2-pyridyl, 4-pyrimidyl, or pyrazinyl group;W is F, Cl, Br, R.sub.4, OR.sub.4, NO.sub.2, NH.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: December 21, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: James H. Jensen, Timothy D. Costello, Leon De Brabander, Jr., Matthew E. Voss